OncoMatch/Clinical Trials/NCT07805551
A Study of HDM2017 Combination Therapy in Advanced Colorectal Cancer
Is NCT07805551 recruiting? Yes, currently enrolling (Sep 2026). This Phase 1/2 trial studies multiple treatments for crc, colorectal cancer.
Treatment: HDM2017 · Bevacizumab · Oxaliplatin · Fluorouracil · Capecitabine · Leucovorin — This is a multicenter, open-label, dose-escalation/dose-expansion, Phase Ib/II study to evaluate the safety, tolerability, PK characteristics, and preliminary anti-tumor efficacy of HDM2017 combination therapy in participants with advanced CRC. The study is divided into two periods: dose escalation (Phase Ib) and dose expansion (Phase II). Phase Ib of this study is a dose-finding study of different HDM2017 combination therapies. The Phase II study will be conducted at a dose determined to be safe and potentially effective in Phase Ib.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Chemotherapy
Other
Cancer type
Colorectal Cancer
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Cannot have received: topoisomerase I inhibitor
Prior or current treatment with topoisomerase I (TOP I) inhibitor drugs
Cannot have received: CDH17-targeted therapy
Prior or current treatment targeting CDH17
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07805551 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior topoisomerase I inhibitor, CDH17-targeted therapy disqualifies patients from enrollment.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages